CLDN18 (Claudin 18)

The developed 1⁸F-FDG PET/CT-based multimodal radiomics model serves as an effective, non-invasive tool for predicting CLDN18.2 expression in GAC. The study validates the hypometabolic nature of CLDN18.2-positive tumors, suggesting this radiomics approach can effectively complement traditional biopsy methods for patient stratification.

P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160

The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.

This study demonstrates that CLDN18.2 exhibits strong diagnostic performance for gastric adenocarcinoma and shows strong correlation with cancer progression. The Cox regression analysis established CLDN18.2 as an independent prognostic factor for patient survival outcomes.

We further discuss synergistic approaches involving genetic engineering, microenvironment modulation, and combination therapies aimed at enhancing efficacy. Finally, we offer perspectives on the future direction of CAR-based therapies, including the development of next-generation constructs, allogeneic "off-the-shelf" products, and personalized combination regimens, underscoring their potential in pancreatic cancer.

The reduction in CD8-positive TILs density around invasive GAS glands indicates an immunologically "cold" tumor microenvironment that may contribute to treatment resistance. The present results provide novel insights into the pathology of GAS that may inform more effective diagnostic approaches and therapeutic strategies for this aggressive malignancy.

These findings obtained from the second-largest cohort study to date suggested that MUC5AC expression was reduced in invasive lesions. Furthermore, MUC5AC expression in EMPD was not associated with the expression of HNF4α, despite its role in inducing MUC5AC expression in normal gastric tissues.

Malignant effusion CBs show favourable intra-patient biomarker consistency over time, supporting their feasibility for longitudinal monitoring. Effusion-based testing shows potential value for potentially identifying candidates for FGFR2b-targeted therapies, pending further clinical validation.

A mean of 3.4 outpatient visits per patient per month was reported (mean follow-up, 6.5 months), 21.0% of patients had an inpatient admission, and 35.5% had an emergency department visit. This study demonstrates substantial disease-related symptom burden and high HRU for patients with CLDN18.2+, HER2-, LA unresectable or mG/GEJ adenocarcinoma.

P2, N=151, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting